

- HRSV. *See* Human respiratory syncytial virus (HRSV) infections
- HSV, 965t
- influenza virus. *See* Influenza
- laryngitis, 234
- lymphadenopathy in, 408
- M. pneumoniae*, 1163, 1164t
- mastoiditis, 230–231, 231f, 900
- in mitral stenosis, 1540
- mucormycosis, 1351
- Nocardia*, 1084–1085, 1085f, 1087t
- nonspecific, 225–226
- nontuberculous mycobacterial, 1130
- oral cavity, 233–234
- parainfluenza virus. *See* Parainfluenza virus infections
- pharyngitis. *See* Pharyngitis
- pneumonia. *See* Pneumonia
- rhinovirus. *See* Rhinovirus infections
- sinusitis. *See* Sinusitis
- sporotrichosis, 1354, 1354t
- Respite care, 65
- Response, to drug, 103e-5
- Response Evaluation Criteria in Solid Tumors (RECIST), 103e-5, 472, 552
- REST, 444e-4
- Restan virus, 1309t
- Restenosis, 296e-1–3, 296e-2f, 1591
- Resting energy expenditure (REE), 95e-1, 98e-4
- Resting (basal) metabolic rate, 73, 74f, 415e-2, 461
- Restitution, 1912
- Restless legs syndrome
- in chronic kidney disease, 1819
 - clinical features of, 188t, 192, 2625
 - diagnosis of, 188t, 192
 - genetic considerations in, 2625
 - incidence of, 2625
 - in pregnancy, 49
 - treatment of, 188t, 192, 2625
- Restriction element, 373e-4
- Restrictive cardiomyopathy
- in amyloidosis, 1566–1567, 1566f, 1567f
 - clinical features of, 1554t, 1573t
 - diagnosis of, 1554t, 1566f, 1573t
 - differential diagnosis of, 1462, 1463t, 1573t, 1576
 - drug-induced, 1567
 - endomyocardial, 1567–1568
 - etiology of, 1565t, 1566
 - fibrotic, 1567
 - genetic considerations in, 1555t
 - in metabolic disorders, 1565–1566
 - overlap with other cardiomyopathies, 1565t
 - pathogenesis of, 1566
 - radiation-related, 1567
 - in systemic sclerosis, 1567
- Resuscitation, ABCs of, 1750
- Resveratrol, 85, 94e-6–7, 94e-6f
- Reptilase
- action of, 759
 - for acute limb ischemia, 1646
 - contraindications to, 1605
 - domain structure of, 759, 759f
 - indications for, 759
 - for myocardial infarction, 1605
- RET gene mutations
- action of, 2329
 - cancers associated with, 101e-3t
 - as drug target, 101e-8
 - genetic testing for, 2342
 - in lung cancer, 508, 509f, 521
 - in MEN 2, 101e-6t, 2251–2252, 2307, 2332, 2336t, 2342, 2472
 - in pheochromocytoma/paraganglioma, 2334f, 2335, 2342
 - prophylactic thyroidectomy in, 2341, 2341t
 - screening tests in, 2341t, 2342
 - in thyroid cancer, 2304, 2305t, 2341
- Reticular activating system (RAS), 1771
- Reticular dysgenesis, 375e-1, 2108
- Reticulate body, 1166, 1166f
- Reticulin stain, 81e-5f
- Reticulocyte(s), 396f
- Reticulocyte count, 81e-2f
- in anemia, 394, 396–397
 - correction of, 396f, 397
 - in hemolytic anemia, 649t, 650
 - reference values for, 2756t
- Reticulocyte production index, 396–397, 396f, 396t, 397t
- Reticuloendothelial system, 626
- Reticulohistiocytosis, multicentric, 365
- Reticulospinal pathway, 155f
- Reticulum cell sarcoma (interdigitating dendritic cell sarcoma), 135e-9
- Retina, 195
- age-related changes in, 40e-2
 - cotton-wool spots in, 40e-3, 40e-3f
 - crystal deposition in, 40e-4
 - detached, 197, 204, 204f
 - detachment of, 40e-5
 - emboli in, 40e-4, 41e-1v
 - examination of, 40e-1, 40e-2, 40e-2t
 - gyrate atrophy of, 434e-3t
 - hard exudates in, 40e-3
 - hemorrhages in, 40e-2–3
 - deep, 40e-3f
 - diseases associated with, 40e-3t
 - in high-altitude illness, 476e-1
 - in infective endocarditis, 200, 201f
 - in malaria, 1373, 1373f
 - superficial, 40e-2f
 - in hypertension, 1622
 - lesions of, 197
 - microaneurysms of, 40e-3
 - neovascularization of, 40e-3–4, 40e-4f
 - radiation-induced damage to, 103e-4
 - vascular sheathing in, 40e-4–5, 40e-4f5
- Retinal artery occlusion, 201, 201f
- Retinaldehyde, 96e-5
- Retinal pigment epithelium, 40e-1
- Retinal vein occlusion, 201, 202f
- Retinitis
- CMV
 - clinical features of, 1192, 1192f
 - in HIV infection, 1267
 - treatment of, 215e-7–8, 1193–1194
 - T. gondii*, 1402, 1403t
- Retinitis pigmentosa, 206, 206f, 431t, 1855
- Retinoblastoma
- hereditary (familial), 101e-2t, 101e-5f, 101e-6, 101e-6t, 440
 - sarcomas and, 119e-1
 - sporadic, 440
- Retinoblastoma protein (Rb), 102e-1
- Retinoblastoma (RB) tumor suppressor protein, 494
- Retinoic acid, 96e-5, 96e-6. *See also* All-*trans*-retinoic acid (ATRA)
- for acne vulgaris, 352
 - in pregnancy, 96e-7
 - for promyelocytic leukemia, 96e-6, 400e-4
 - for squamous cell carcinoma, 502
- Retinoic acid-inducible gene-1-like receptors (RLRs), 372e-2, 372e-4, 372e-4t
- Retinoic acid receptors, 96e-6, 444e-5, 477
- Retinoid acid X receptors (RXRs), 2287, 2287f
- Retinoids, 96e-5, 216, 348
- Retinol, 477
- Retinol-binding protein, 462
- Retinopathy
- cancer-associated (paraneoplastic), 614t, 619
 - CMV, 1192, 1192f
 - diabetic. *See* Diabetic retinopathy
 - diseases associated with, 40e-2–3, 40e-3t
 - hypertensive, 201, 201f, 1622
 - Purtscher's like, 40e-4
- Retrolbulbar tumor, of optic nerve, 206
- Retrocalcaneal bursitis, 2247
- Retrocollis, 2620
- Retrograde amnesia, 182
- Retrograde ejaculation, 325, 2427
- Retromer complex, 444e-10
- Retropertoneal fibrosis, 391e-1t, 391e-2
- Retropertoneal hemorrhage, 733
- Retropharyngeal abscess, 235
- Retropharyngeal soft tissue mass, 441e-32f
- Retropharyngeal space infections, 235
- Retrovirus(es), 225e-1
- cancer development and, 101e-2, 101e-7
 - classification of, 225e-1, 225e-1t
 - gene expression and replication in, 214e-5, 225e-1–2, 225e-2f, 225e-3f
 - for gene therapy delivery, 91e-1t, 214e-9, 225e-2
- HIV. *See* HIV
- HLTV-1. *See* Human T-cell lymphotropic virus (HTLV-1)
- inflammatory myopathies and, 2197
 - life cycle of, 225e-1, 225e-2f
 - myopathies associated with, 2657
 - structure of, 214e-2t, 214e-3f, 225e-1, 225e-3f
- Rett's syndrome, 431, 444e-1, 444e-4
- Reverse cholesterol transport, 2437–2438
- Reverse isolation, 492
- Reverse straight-leg raising sign, 113
- Reverse T₃ (rT₃), 2283f
- Reverse transcriptase enzyme, HIV, 1216, 1219
- Reverse transcriptase inhibitors. *See* Combination antiretroviral therapy (cART)
- Reverse transcriptase polymerase chain reaction (RT-PCR), 1247, 1247t
- Reverse transcription, 214e-5
- "Reverse type", 138e-2
- Reverse vaccinology, 776
- Reversible cerebral vasoconstriction syndrome, 2568
- Reversible posterior leukoencephalopathy, 1793, 2568, 2584
- rev* gene, 225e-3f, 1219f
- Revised Cardiac Risk Index (RCRI), 52, 53f, 53t
- Rev protein, 225e-2
- Rewarming
- for frostbite, 478e-4, 478e-4t
 - for hypothermia, 478e-3, 478e-3t
 - for shock, 1751
- Rex proteins, 214e-5, 214e-7, 225e-2
- Reye's syndrome, 126, 1184, 1185, 1212–1213
- Rh0(D) immune globulin, for immune thrombocytopenic purpura, 728
- Rhabdomyolysis
- acute kidney injury in, 1804, 1805, 1806t, 1810
 - hyperkalemia in, 310
 - hypernatremic, 303
 - hypocalcemia in, 315
 - hypokalemia and, 307
 - hypophosphatemia-induced, 2459–2460
 - in influenza, 1212
 - treatment of, 1810
- Rhabdomyoma, cardiac, 289e-2
- Rhabdomyosarcoma, 101e-3t, 119e-1, 119e-2. *See also* Soft tissue sarcoma
- Rhabdoviruses
- gene expression and replication in, 214e-4
 - lyssaviruses, 1299, 1304
 - structure of, 214e-2t, 214e-3f, 1305
- Rhabdovirus infections
- Chandipura virus infection, 1316
 - clinical syndromes of, 1312t
 - geographic distribution of, 1311–1312t
 - rabies. *See* Rabies
 - vesicular stomatitis virus infection, 1299, 1304
- RHAG gene mutations, 653, 653t
- Rh blood group system, 138e-1, 138e-1t
- RHC (red hair color) phenotype, 494
- Rheumatic fever, 2149
- cardiovascular complications of
 - antithrombotic prophylaxis for, 2566t
 - aortic valve disease, 1529
 - diagnosis of, 2151, 2151f, 2151t
 - echocardiography in, 2151, 2151f, 2151t, 2154v
 - global considerations in, 16, 964, 964f, 1501, 2149
 - heart failure, 2153
 - mitral stenosis, 51e-6, 1539, 2151, 2154v. *See also* Mitral stenosis
 - pathogenesis of, 2149–2150, 2150f
 - pericarditis, 1575
 - SA node dysfunction, 1467, 1467t